Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma.

Eur Urol Open Sci · 2021 · PMC8385286 · PMID 34467233

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The subgroup analyses consistently showed a trend in favor of the lenvatinib plus everolimus combination; however, the differences were not always statistically significant, which could be attributed to the relatively small number of subjects in each subgroup.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.